Company / R&D per Share
Incyte R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$10.60
FY2025
5-year range
$6.64 / $11.62
FY2021-FY2025
Trend
-8.8%
vs FY2024
Sector context
#16 of 208
Health Care
What the data says
Among 208 Health Care companies, Incyte is in the top 8% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $3.12 in FY2016 to $11.62 in FY2024.
Based on SEC 10-K filings.
10.60 in FY2025 with a 5-year CAGR of +13.8%. Top quartile in the Health Care sector.
Improved from $7.31 to $10.60 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +13.8%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 208This company $10.60 Sector average $28.82
▼
-63.2% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 8.8% year-over-year.
- Ranks #16 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.7%
- Strong return on equity: 25.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.60 | -8.8% |
| FY2024 | $11.62 | +59.1% |
| FY2023 | $7.31 | +1.9% |
| FY2022 | $7.17 | +8.0% |
| FY2021 | $6.64 | +19.9% |
| FY2020 | $5.54 | -10.9% |
| FY2019 | $6.22 | +9.7% |
| FY2018 | $5.67 | -19.2% |
| FY2017 | $7.02 | +125.3% |
| FY2016 | $3.12 | +11.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026